-
Active Trials
-
Phase 3
-
Phase 2
-
Phase 1
-
Results Pending
📊
Pipeline Summary
Expected Approvals
FDA Decision 1 upcoming PDUFA date
ZIIHERA (zanidatamab) first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) sBLA
Clinical Trials
Loading...